{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T18:05:32Z","timestamp":1747159532629,"version":"3.40.5"},"reference-count":13,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","ejinme.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Internal Medicine"],"published-print":{"date-parts":[[2024,5]]},"DOI":"10.1016\/j.ejim.2024.03.005","type":"journal-article","created":{"date-parts":[[2024,3,8]],"date-time":"2024-03-08T21:23:15Z","timestamp":1709932995000},"page":"60-62","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Direct oral anticoagulants: The new standard of care for cancer associated thrombosis"],"prefix":"10.1016","volume":"123","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5930-7304","authenticated-orcid":false,"given":"Marcello","family":"Di Nisio","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1915-6681","authenticated-orcid":false,"given":"Agnes Y","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejim.2024.03.005_bib0001","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/s41572-022-00336-y","article-title":"Cancer-associated venous thromboembolism","volume":"8","author":"Khorana","year":"2022","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.ejim.2024.03.005_bib0002","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/j.ejvs.2018.11.004","article-title":"Editor's Choice - a systematic review and meta-analysis of the efficacy and safety of anticoagulation in the treatment of venous thromboembolism in patients with cancer","volume":"57","author":"Kirkilesis","year":"2019","journal-title":"Eur J Vasc Endovasc Surg"},{"key":"10.1016\/j.ejim.2024.03.005_bib0003","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/j.annonc.2022.12.014","article-title":"Venous thromboembolism in cancer patients: ESMO clinical practice guideline","volume":"34","author":"Falanga","year":"2023","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejim.2024.03.005_bib0004","doi-asserted-by":"crossref","first-page":"3063","DOI":"10.1200\/JCO.23.00294","article-title":"Venous thromboembolism prophylaxis and treatment in patients with cancer: ASCO guideline update","volume":"41","author":"Key","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejim.2024.03.005_bib0005","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1182\/bloodadvances.2020003442","article-title":"Alonso-Coello P.American society of hematology 2021 guidelines for management of venous thromboembolism: prevention and treatment in patients with cancer","volume":"5","author":"Lyman","year":"2021","journal-title":"Blood Adv"},{"key":"10.1016\/j.ejim.2024.03.005_bib0006","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1002\/rth2.12002","article-title":"Current practice patterns and patient persistence with anticoagulant treatments for cancer-associated thrombosis","volume":"1","author":"Khorana","year":"2017","journal-title":"Res Pract Thromb Haemost"},{"key":"10.1016\/j.ejim.2024.03.005_bib0007","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1182\/blood.2020005819","article-title":"Direct oral anticoagulants for cancer-associated venous thromboembolism: a systematic review and meta-analysis","volume":"136","author":"Mulder","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.ejim.2024.03.005_bib0008","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1001\/jama.2023.7843","article-title":"Direct oral anticoagulants vs low-molecular-weight heparin and recurrent VTE in patients with cancer: a randomized clinical trial","volume":"329","author":"Schrag","year":"2023","journal-title":"JAMA"},{"key":"10.1016\/j.ejim.2024.03.005_bib0009","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.ejim.2024.01.012","article-title":"on behalf of the COMMAND VTE Registry-2 Investigators. Transition of management strategies and long-term outcomes in cancer-associated venous thromboembolism from the warfarin era to the direct oral anticoagulant era","volume":"123","author":"Chatani","year":"2024","journal-title":"Eur J Intern Med"},{"key":"10.1016\/j.ejim.2024.03.005_bib0010","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.25283","article-title":"Comparative effectiveness of anticoagulants in patients with cancer-associated thrombosis","volume":"6","author":"Riaz","year":"2023","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.ejim.2024.03.005_bib0011","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1016\/j.jaccao.2023.09.003","article-title":"Cancer-associated thrombosis: trends in clinical features, treatment, and outcomes from 2001 to 2020","volume":"5","author":"Bertoletti","year":"2023","journal-title":"JACC CardioOncol"},{"key":"10.1016\/j.ejim.2024.03.005_bib0012","doi-asserted-by":"crossref","first-page":"1968","DOI":"10.1182\/blood-2014-04-571232","article-title":"Direct oral anticoagulants compared with vitamin K antagonists for acute venous thromboembolism: evidence from phase 3 trials","volume":"124","author":"van Es","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.ejim.2024.03.005_bib0013","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1111\/jth.15153","article-title":"Anticoagulant medication adherence for cancer-associated thrombosis: a comparison of LMWH to DOACs","volume":"19","author":"Schaefer","year":"2021","journal-title":"J Thromb Haemost"}],"container-title":["European Journal of Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0953620524000955?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0953620524000955?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,5,7]],"date-time":"2024-05-07T13:44:20Z","timestamp":1715089460000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0953620524000955"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5]]},"references-count":13,"alternative-id":["S0953620524000955"],"URL":"https:\/\/doi.org\/10.1016\/j.ejim.2024.03.005","relation":{},"ISSN":["0953-6205"],"issn-type":[{"type":"print","value":"0953-6205"}],"subject":[],"published":{"date-parts":[[2024,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Direct oral anticoagulants: The new standard of care for cancer associated thrombosis","name":"articletitle","label":"Article Title"},{"value":"European Journal of Internal Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejim.2024.03.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 European Federation of Internal Medicine. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}